Green tea minimally affects biomarkers of inflammation in obese subjects with metabolic syndrome

Nutrition

Volumn 27, Issue 2, 2011, Pages 206-213

  Basu, Arpita ^a   Du, Mei ^b   Sanchez, Karah ^a   Leyva, Misti J ^b   Betts, Nancy M ^a   Blevins, Steve ^b   Wu, Mingyuan ^b   Aston, Christopher E ^b   Lyons, Timothy J ^b  

^a OKLAHOMA STATE UNIVERSITY   (United States)

^b UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

Green tea; Inflammation; Metabolic syndrome; Serum amyloid A

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; GREEN TEA EXTRACT; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; LEPTIN; SERUM AMYLOID A; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; ARTICLE; BEVERAGE; BODY MASS; CLINICAL ARTICLE; DIET SUPPLEMENTATION; DISEASE MARKER; DRUG EFFECT; DRUG TOLERABILITY; FEMALE; HUMAN; INFLAMMATION; MALE; METABOLIC SYNDROME X; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TEA; THERAPY EFFECT;

ADULT; ANTIOXIDANTS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CAMELLIA SINENSIS; CARDIOVASCULAR DISEASES; CATECHIN; FEMALE; HUMANS; INFLAMMATION; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-1BETA; INTERLEUKIN-6; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; PHYTOTHERAPY; PLANT EXTRACTS; SINGLE-BLIND METHOD; TEA; VASCULAR CELL ADHESION MOLECULE-1;

CAMELLIA SINENSIS;

EID: 78650825302     PISSN: 08999007     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nut.2010.01.015     Document Type: Article

References (81)

1. Thielecke F., Boschmann M. The potential role of green tea catechins in the prevention of the metabolic syndrome-a review. Phytochemistry 2009, 70:11-24.
2. Wolfram S. Effects of green tea and EGCG on cardiovascular and metabolic health. J Am Coll Nutr 2007, 26:373S-388S.
3. Crespy V., Williamson G. A review of the health effects of green tea catechins in in vivo animal models. J Nutr 2004, 134:3431S-3440S.
4. Rana J.S., Nieuwdorp M., Jukema J.W., Kastelein J.J. Cardiovascular metabolic syndrome--an interplay of, obesity, inflammation, diabetes and coronary heart disease. Diabetes Obes Metab 2007, 9:218-232.
5. Buscemi S., Verga S., Cottone S., Azzolina V., Buscemi B., Gioia D., et al. Glycaemic variability and inflammation in subjects with metabolic syndrome. Acta Diabetol 2009, 46:55-61.
6. Wu C.H., Lu F.H., Chang C.S., Chang T.C., Wang R.H., Chang C.J. Relatioship among habitual tea consumption, percent body fat, and body fat distribution. Obes Res 2003, 11:1088-1095.
7. Iso H., Date C., Wakai K., Fukui M., Tamakoshi A. The relationship between green tea and total caffeine intake and risk for self reported type 2 diabetes among Japanese adults. Ann Intern Med 2006, 144:554-562.
8. Yamaji T., Mizoue T., Tabata S., Ogawa S., Yamaguchi K., Shimizu E., et al. Coffee consumption and glucose tolerance status in middle-aged Japanese men. Diabetologia 2004, 47:2145-2151.
9. Yang Y.C., Lu F.H., Wu J.S., Wu C.H., Chang C.J. The protective effect of habitual tea consumption on hypertension. Arch Intern Med 2004, 164:1534-1540.
10. Imai K., Nakachi K. Cross sectional study of effects of drinking green tea on cardiovascular and liver diseases. BMJ 1995, 310:693-696.
11. Sasazuki S., Kodama H., Yoshimasu K., Liu Y., Washio M., Tanaka K., et al. Relation between green tea consumption and the severity of coronary atherosclerosis among Japanese men and women. Ann Epidemiol 2000, 10:401-408.
12. Kuriyama S., Shimazu T., Ohmori K., Kikuchi N., Nakaya N., Nishino Y., et al. Green tea consumption and mortality due to cardiovascular disease, cancer, and all causes in Japan: the Ohsaki study. JAMA 2006, 296:1255-1265.
13. Sesso H.D., Gaziano J.M., Buring J.E., Hennekens C.H. Coffee and tea intake and the risk of myocardial infarction. Am J Epidemiol 1999, 149:162-167.
14. Shimazu T., Kuriyama S., Hozawa A., Ohmori K., Sato Y., Nakaya N., et al. Dietary patterns and cardiovascular disease mortality in Japan: a prospective cohort study. Int J Epidemiol 2007, 36:600-609.
15. Nagao T., Komine Y., Soga S., Meguro S., Hase T., Tanaka Y., et al. Ingestion of a tea rich in catechins leads to a reduction in body fat and malondialdehyde-modified LDL in men. Am J Clin Nutr 2005, 81:122-129.
16. Westerterp-Plantenga M.S., Lejeune M.P., Kovacs E.M. Body weight loss and weight maintenance in relation to habitual caffeine intake and green tea supplementation. Obes Res 2005, 13:1195-1204.
17. Auvichayapat P., Prapochanung M., Tunkamnerdthai O., Sripanidkulchai B.O., Auvichayapat N., Thinkhamrop B., et al. Effectiveness of green tea on weight reduction in obese Thais: a randomized, controlled trial. Physiol Behav 2008, 93:486-491.
18. Fukino Y., Shimbo M., Aoki N., Okubo T., Iso H. Randomized controlled trial for an effect of green tea consumption on insulin resistance and inflammation markers. J Nutr Sci Vitaminol (Tokyo) 2005, 51:335-342.
19. Fukino Y., Ikeda A., Maruyama K., Aoki N., Okubo T., Iso H. Randomized controlled trial for an effect of green tea-extract powder supplementation on glucose abnormalities. Eur J Clin Nutr 2008, 62:953-960.
20. Unno T., Tago M., Suzuki Y., Nozawa A., Sagesaka Y.M., Kakuda T., et al. Effect of tea catechins on postprandial plasma lipid responses in human subjects. Br J Nutr 2005, 93:543-547.
21. Kim W., Jeong M.H., Cho S.H., Yun J.H., Chae H.J., Ahn Y.K., et al. Effect of green tea consumption on endothelial function and circulating endothelial progenitor cells in chronic smokers. Circ J 2006, 70:1052-1057.
22. Widlansky M.E., Hamburg N.M., Anter E., Holbrook M., Kahn D.F., Elliott J.G., et al. Acute EGCG supplementation reverses endothelial dysfunction in patients with coronary artery disease. J Am Coll Nutr 2007, 26:95-102.
23. Lee W., Min W.K., Chun S., Lee Y.W., Park H., Lee D.H., et al. Long-term effects of green tea ingestion on atherosclerotic biological markers in smokers. Clin Biochem 2005, 38:84-87.
24. de Maat M.P., Pijl H., Kluft C., Princen H.M. Consumption of black and green tea had no effect on inflammation, haemostasis and endothelial markers in smoking healthy individuals. Eur J Clin Nutr 2000, 54:757-763.
25. Alexopoulos N., Vlachopoulos C., Aznaouridis K., Baou K., Vasiliadou C., Pietri P., et al. The acute effect of green tea consumption on endothelial function in healthy individuals. Eur J Cardiovasc Prev Rehabil 2008, 15:300-305.
26. Ryu O.H., Lee J., Lee K.W., Kim H.Y., Seo J.A., Kim S.G., et al. Effects of green tea consumption on inflammation, insulin resistance and pulse wave velocity in type 2 diabetes patients. Diabetes Res Clin Pract 2006, 71:356-358.
27. Choo J.J. Green tea reduces body fat accretion caused by high-fat diet in rats through beta-adrenoceptor activation of thermogenesis in brown adipose tissue. J Nutr Biochem 2003, 14:671-676.
28. Klaus S., Pultz S., Thone-Reineke C., Wolfram S. Epigallocatechin gallate attenuates diet-induced obesity in mice by decreasing energy absorption and increasing fat oxidation. Int J Obes Relat Metab Disord 2005, 29:615-623.
29. Yamabe N., Yokozawa T., Oya T., Kim M. Therapeutic potential of (-)-epigallocatechin 3-O-gallate on renal damage in diabetic nephropathy model rats. J Pharmacol Exp Ther 2006, 319:228-236.
30. Chakravarthy B.K., Gupta S., Gambhir S.S., Gode K.D. The prophylactic action of (-)-epicatechin against alloxan induced diabetes in rats. Life Sci 1981, 29:2043-2047.
31. Potenza M.A., Marasciulo F.L., Tarquinio M., Tiravanti E., Colantuono G., Federici A., et al. EGCG, a green tea polyphenol, improves endothelial function and insulin sensitivity, reduces blood pressure, and protects against myocardial I/R injury in SHR. Am J Physiol Endocrinol Metab 2007, 292:E1378-E1387.
32. Negishi H., Xu J.W., Ikeda K., Njelekela M., Nara Y., Yamori Y. Black and green tea polyphenols attenuate blood pressure increases in stroke-prone spontaneously hypertensive rats. J Nutr 2004, 134:38-42.
33. Yang M., Wang C., Chen H. Green, oolong and black tea extracts modulate lipid metabolism in hyperlipidemia rats fed high-sucrose diet. J Nutr Biochem 2001, 12:14-20.
34. Ramadan G., El-Beih N.M., Abd El-Ghffar E.A. Modulatory effects of black v. green tea aqueous extract on hyperglycaemia, hyperlipidaemia and liver dysfunction in diabetic and obese rat models. Br J Nutr 2009, 1-9. [Epub ahead of print].
35. Ramesh E., Geraldine P., Thomas P.A. Regulatory effect of epigallocatechin gallate on the expression of C-reactive protein and other inflammatory markers in an experimental model of atherosclerosis. Chem Biol Interact 2009, [Epub ahead of print].
36. Senthil Kumaran V., Arulmathi K., Sundarapandiyan R., Kalaiselvi P. Attenuation of the inflammatory changes and lipid anomalies by epigallocatechin-3-gallate in hypercholesterolemic diet fed aged rats. Exp Gerontol 2009, [Epub ahead of print].
37. Nguyen X.M., Lane J., Smith B.R., Nguyen N.T. Changes in inflammatory biomarkers across weight classes in a representative US population: a link between obesity and inflammation. J Gastrointest Surg 2009, 13:1205-1212.
38. Grundy S.M., Cleeman J.I., Daniels S.R., Donato K.A., Eckel R.H., Franklin B.A., et al. American Heart Association; National Heart, Lung, and Blood Institute: Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005, 112:2735-2752.
39. Seeram N.P., Henning S.M., Niu Y., Lee R., Scheuller H.S., Heber D. Catechin and caffeine content of green tea dietary supplements and correlation with antioxidant capacity. J Agric Food Chem 2006, 54:1599-1603.
40. Wang X., Chai H., Wang Z., Lin P.H., Yao Q., Chen C. Serum amyloid A induces endothelial dysfunction in porcine coronary arteries and human coronary artery endothelial cells. Am J Physiol Heart Circ Physiol 2008, 295:H2399-H2408.
41. Kim F., Pham M., Maloney E., Rizzo N.O., Morton G.J., Wisse B.E., et al. Vascular inflammation, insulin resistance, and reduced nitric oxide production precede the onset of peripheral insulin resistance. Arterioscler Thromb Vasc Biol 2008, 28:1982-1988.
42. Poitou C., Viguerie N., Cancello R., De Matteis R., Cinti S., Stich V., et al. Serum amyloid A: production by human white adipocyte and regulation by obesity and nutrition. Diabetologia 2005, 48:519-528.
43. Coetzee G.A., Strachan A.F., van der Westhuyzen D.R., Hoppe H.C., Jeenah M.S., de Beer F.C. Serum amyloid A-containing human high density lipoprotein 3. Density, size, and apolipoprotein composition. J Biol Chem 1986, 261:9644-9651.
44. Boynton A., Neuhouser M.L., Wener M.H., Wood B., Sorensen B., Chen-Levy Z., et al. Associations between healthy eating patterns and immune function or inflammation in overweight or obese postmenopausal women. Am J Clin Nutr 2007, 86:1445-1455.
45. Varilek G.W., Yang F., Lee E.Y., deVilliers W.J., Zhong J., Oz H.S., et al. Green tea polyphenol extract attenuates inflammation in interleukin-2-deficient mice, a model of autoimmunity. J Nutr 2001, 131:2034-2039.
46. Auclair S., Milenkovic D., Besson C., Chauvet S., Gueux E., Morand C., et al. Catechin reduces atherosclerotic lesion development in apo E-deficient mice: a transcriptomic study. Atherosclerosis 2009, 204:e21-e27.
47. Nantz M.P., Rowe C.A., Bukowski J.F., Percival S.S. Standardized capule of Camellia sinensis lowers cardiovascular risk factors in a randomized, double-blind, placebo-controlled study. Nutrition 2009, 25:147-154.
48. Jenkins D.J., Kendall C.W., Connelly P.W., Jackson C.J., Parker T., Faulkner D., et al. Effects of high- and low-isoflavone (phytoestrogen) soy foods on inflammatory biomarkers and proinflammatory cytokines in middle-aged men and women. Metabolism 2002, 51:919-924.
49. Johnson B.D., Kip K.E., Marroquin O.C., Ridker P.M., Kelsey S.F., Shaw L.J., et al. National Heart, Lung, and Blood Institute. Serum amyloid A as a predictor of coronary artery disease and cardiovascular outcome in women: the National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE). Circulation 2004, 109:726-732.
50. Morrow D.A., Rifai N., Antman E.M., Weiner D.L., McCabe C.H., Cannon C.P., et al. Serum amyloid A predicts early mortality in acute coronary syndromes: A TIMI 11A substudy. J Am Coll Cardiol 2000, 35:358-362.
51. Koenig W., Sund M., Fröhlich M., Fischer H.G., Löwel H., Döring A., et al. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999, 99:237-242.
52. Ridker P.M., Hennekens C.H., Buring J.E., Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000, 342:836-843.
53. Pearson T.A., Mensah G.A., Alexander R.W., Anderson J.L., Cannon R.O., Criqui M., et al. Centers for Disease Control and Prevention; American Heart Association. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003, 107:499-511.
54. Chun O.K., Chung S.J., Claycombe K.J., Song W.O. Serum C-reactive protein concentrations are inversely associated with dietary flavonoid intake in U.S. adults. J Nutr 2008, 138:753-760.
55. di Giuseppe R., Di Castelnuovo A., Centritto F., Zito F., De Curtis A., Costanzo S., et al. Regular consumption of dark chocolate is associated with low serum concentrations of C-reactive protein in a healthy Italian population. J Nutr 2008, 138:1939-1945.
56. Widlansky M.E., Duffy S.J., Hamburg N.M., Gokce N., Warden B.A., Wiseman S., et al. Effects of black tea consumption on plasma catechins and markers of oxidative stress and inflammation in patients with coronary artery disease. Free Radic Biol Med 2005, 38:499-506.
57. Ridker P.M., Rifai N., Stampfer M.J., Hennekens C.H. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000, 101:1767-1772.
58. Ferroni P., Basili S., Vieri M., Martini F., Labbadia G., Bellomo A., et al. Soluble P-selectin and proinflammatory cytokines in patients with polygenic type IIa hypercholesterolemia. Haemostasis 1999, 29:277-285.
59. Mulvihill N.T., Foley J.B., Murphy R., Crean P., Walsh M. Evidence of prolonged inflammation in unstable angina and non-Q wave myocardial infarction. J Am Coll Cardiol 2000, 36:1210-1216.
60. Blankenberg S., Rupprecht H.J., Bickel C., Peetz D., Hafner G., Tiret L., et al. Circulating cell adhesion molecules and death in patients with coronary artery disease. Circulation 2001, 104:1336-1342.
61. Ahmed S., Marotte H., Kwan K., Ruth J.H., Campbell P.L., Rabquer B.J., et al. Epigallocatechin-3-gallate inhibits IL-6 synthesis and suppresses transsignaling by enhancing soluble gp130 production. Proc Natl Acad Sci USA 2008, 105:14692-14697.
62. Neyestani T.R., Gharavi A., Kalayi A. Selective effects of tea extract and its phenolic compounds on human peripheral blood mononuclear cell cytokine secretions. Int J Food Sci Nutr 2008, 1-10. [Epub ahead of print].
63. Ludwig A., Lorenz M., Grimbo N., Steinle F., Meiners S., Bartsch C., et al. The tea flavonoid epigallocatechin-3-gallate reduces cytokine-induced VCAM-1 expression and monocyte adhesion to endothelial cells. Biochem Biophys Res Commun 2004, 316:659-665.
64. Gonçalves F.M., Jacob-Ferreira A.L., Gomes V.A., Casella-Filho A., Chagas A.C., Marcaccini A.M., et al. Increased circulating levels of matrix metalloproteinase (MMP)-8, MMP-9, and pro-inflammatory markers in patients with metabolic syndrome. Clin Chim Acta 2009, 403:173-177.
65. Balducci S., Zanuso S., Nicolucci A., Fernando F., Cavallo S., Cardelli P., et al. Anti-inflammatory effect of exercise training in subjects with type 2 diabetes and the metabolic syndrome is dependent on exercise modalities and independent of weight loss. Nutr Metab Cardiovasc Dis 2009, [Epub ahead of print].
66. Koh K.K., Han S.H., Chung W.J., Ahn J.Y., Jin D.K., Kim H.S., et al. Comparison of effects of losartan, irbesartan, and candesartan on flow-mediated brachial artery dilation and on inflammatory and thrombolytic markers in patients with systemic hypertension. Am J Cardiol 2004, 93:1432-1435.
67. Marketou M.E., Zacharis E.A., Koukouraki S., Stathaki M.I., Arfanakis D.A., Kochiadakis G.E., et al. Effect of angiotensin-converting enzyme inhibitors on systemic inflammation and myocardial sympathetic innervation in normotensive patients with type 2 diabetes mellitus. J Hum Hypertens 2008, 22:191-196.
68. Matsushita K., Yatsuya H., Tamakoshi K., Wada K., Otsuka R., Takefuji S., et al. Comparison of circulating adiponectin and proinflammatory markers regarding their association with metabolic syndrome in Japanese men. Arterioscler Thromb Vasc Biol 2006, 26:871-876.
69. Saltevo J., Vanhala M., Kautiainen H., Kumpusalo E., Laakso M. Gender differences in C-reactive protein, interleukin-1 receptor antagonist and adiponectin levels in the metabolic syndrome: a population-based study. Diabet Med 2008, 25:747-750.
70. Koh S.B., Park J.K., Yoon J.H., Chang S.J., Oh S.S., Kim J.Y., et al. A serious link between adiponectin levels and metabolic syndrome in a Korean nondiabetic population. Metabolism 2009, [Epub ahead of print].
71. Hung J., McQuillan B.M., Thompson P.L., Beilby J.P. Circulating adiponectin levels associate with inflammatory markers, insulin resistance and metabolic syndrome independent of obesity. Int J Obes (Lond) 2008, 32:772-779.
72. Cho S.Y., Park P.J., Shin H.J., Kim Y.K., Shin D.W., Shin E.S., et al. (-)-Catechin suppresses expression of Kruppel-like factor 7 and increases expression and secretion of adiponectin protein in 3T3-L1 cells. Am J Physiol Endocrinol Metab 2007, 292:E1166-E1172.
73. Dvoráková-Lorenzová A., Suchánek P., Havel P.J., Stávek P., Karasová L., Valenta Z., et al. The decrease in C-reactive protein concentration after diet and physical activity induced weight reduction is associated with changes in plasma lipids, but not interleukin-6 or adiponectin. Metabolism 2006, 55:359-365.
74. Kovacova Z., Vitkova M., Kovacikova M., Klimcakova E., Bajzova M., Hnevkovska Z., et al. Secretion of adiponectin multimeric complexes from adipose tissue explants is not modified by very low calorie diet. Eur J Endocrinol 2009, 160:585-592.
75. Ntyintyane L., Panz V., Raal F.J., Gill G. Leptin, adiponectin, and high-sensitivity C-reactive protein in relation to the metabolic syndrome in urban South African blacks with and without coronary artery disease. Metab Syndr Relat Disord 2009, 7:243-248.
76. Corica F., Allegra A., Corsonello A., Buemi M., Calapai G., Ruello A., et al. Relationship between plasma leptin levels and the tumor necrosis factor-alpha system in obese subjects. Int J Obes Relat Metab Disord 1999, 23:355-360.
77. Esteghamati A., Khalilzadeh O., Anvari M., Rashidi A., Mokhtari M., Nakhjavani M. Association of serum leptin levels with homeostasis model assessment-estimated insulin resistance and metabolic syndrome: the key role of central obesity. Metab Syndr Relat Disord 2009, 7:447-452.
78. Stenholm S., Koster A., Alley D.E., Visser M., Maggio M., Harris T.B., et al. Adipocytokines and the metabolic syndrome among older persons with and without obesity--the InCHIANTI Study. Clin Endocrinol (Oxf) 2009, [Epub ahead of print].
79. Zhou J.R., Li L., Pan W. Dietary soy and tea combinations for prevention of breast and prostate cancers by targeting metabolic syndrome elements in mice. Am J Clin Nutr 2007, 86:s882-s888.
80. Alberti K.G., Eckel R.H., Grundy S.M., Zimmet P.Z., Cleeman J.I., Donato K.A., et al. International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009, 120:1640-1645.
81. Rai A.J., Udar N., Saad R., Fleisher M. A multiplex assay for detecting genetic variations in CYP2C9, VKORC1, and GGCX involved in warfarin metabolism. Clin Chem 2009, 55:823-826.